Uterine Artery Occlusion for Fibroid Related Bleeding

Ethicon

Status

Terminated

Conditions

Uterine Fibroids

Menorrhagia

Treatments

Device: Doppler-Guided Uterine Artery Occlusion Device

Study type

Interventional

Funder types

Industry

Identifiers

NCT00496067

300-06-008

Details and patient eligibility

About

The primary objective of this study is to evaluate the safety and effectiveness of Doppler guided Uterine Artery Occlusion (D-UAO) as treatment for the reduction of fibroid-associated symptoms.

Full description

DUAO is intended for bilateral occlusion of the uterine arteries

Enrollment

91 patients

Sex

Female

Ages

25 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

25 to 50 years of age
Subject has a negative urine or blood pregnancy test prior to the procedure. At the time of enrollment to the study, the subject has no intent of further childbearing and intends to use appropriate contraception throughout the first 12 months of the study period (unless sterilized)
Normal pap smear within 36 months of study procedure (most recent)
Cervix suitable for tenaculum placement as determined by pelvic exam (adequate length of cervix, absence of cervical fibroid/lower fibroid to prevent clamp placement)
At least one intra-mural or sub-serosal or sub-mucosal uterine fibroid with a minimum diameter of greater than or equal to 3 cm, and all fibroids with a diameter less than or equal to 8cm with a prevailing pathology (e.g., as opposed to adenomyosis) of fibroids determined through ultrasound
Symptomatic subject presenting with at least one of the following fibroid symptoms: pelvic pressure, menorrhagia, metrorrhagia, pelvic pain, increasing abdominal girth or dyspareunia due to fibroids.
Subject has evidence of bilateral ureteric flow
Subject agrees to participate in the study, including completion of all study-related procedures and evaluations, and documents this agreement by signing the Ethics Committee-approved informed consent.

Exclusion criteria

Pregnancy as confirmed by positive urine or blood pregnancy test
Menopausal as defined by elevated follicle-stimulating hormone (FSH) and decreased oestradiol hormone levels as determined by the hospital local laboratory reference range criteria
Presence of any pedunculated sub-mucosal or pedunculated sub-serosal fibroid(s) as determined by MRI, ultrasound or hysteroscopy
Presence of an intra-uterine device (IUD)
Any hydronephrosis as determined on renal ultrasound prior to the procedure
Clinical history of any thrombo-embolic disease or known thrombophilia
Blood Urine Nitrogen (BUN) greater than 7.2mmol/L* and/or serum creatinine greater than 106μmol/L* unresolved with change in diet or hydration
History or current evidence of gynecologic malignancy (confirmed by hysteroscopy or endometrial biopsy), atypical endometrial hyperplasia, or chronic pelvic inflammatory disease
Pelvic mass outside the uterus other than uterine fibroids
Any current acute or chronic systemic infection or localized pelvic infection, including a urinary tract infection
Use of Gonadotropin-Releasing Hormone (GnRH) agonist, danozol or mifepristone within 6-months prior to the start of the study procedure
Using anticoagulation therapy (except over the counter treatments (e.g. aspirin)), or have an underlying bleeding disorder
Unsuitable for MRI examination (e.g. severe claustrophobia, non-MRI-compatible implanted metalloid devices)
Prior endometrial ablation, uterine artery embolization, or uterine artery ligation
Poor procedural candidate due to medical conditions as determined by the investigator (e.g. anesthesia class, renal insufficiency, heart disease);